首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1922461

日本神經生物標記市場按類型、應用、最終用途和地區分類，2026-2034年

Japan Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 116 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本神經生物標記市場規模達6.239億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到9.868億美元，2026年至2034年的複合年成長率為5.23%。有效治療方案的日益普及和對更快藥物研發的需求不斷成長是推動市場成長的主要因素。

存在於血液或腦脊髓液中的神經生物標記可以識別腦部疾病並追蹤其進展。這些生物標記主要來自基因突變、代謝物水平、腦部影像、蛋白質表現變化以及轉譯後修飾。神經生物標記在藥物研發過程中發揮著重要的臨床應用作用，因為它們能夠識別實驗藥物的生物學反應，並有助於發現新的治療性介入標靶。科學家目前正在分析這些生物標記的濃度，以實現非侵入性檢測、早期診斷和個人化治療。

日本神經生物標記市場的發展趨勢：

由於中風、運動神經元疾病（MND）、阿茲海默症（AD）、帕金森氏症（PD）和亨廷頓舞蹈症（HD）等神經系統疾病的盛行率不斷上升，日本的神經生物標記市場正經歷顯著成長。神經系統疾病的激增催生了對加速藥物研發的迫切需求，從而推動了市場成長。此外，生物標記在評估新藥和治療方法的有效性方面發揮關鍵作用，極大地促進了這一成長勢頭。微創手術和個人化醫療實踐的廣泛應用也是該地區市場擴張的關鍵促進因素。此外，由於各種神經系統疾病通常具有通用特徵，因此對能夠區分特定疾病及其亞型的多種生物標記的需求日益成長，進一步刺激了市場需求。同時，質譜和成像診斷技術的進步使得快速評估大腦中多種生化標記和結構變化成為可能，從而提高了診斷能力。預計未來幾年，隨著數位生物標記的採用和臨床試驗數量的不斷增加，這將進一步推動日本神經生物標記市場的成長。

本報告解答的關鍵問題

日本神經生物標記市場的趨勢和未來前景如何？
新冠疫情對日本神經生物標記市場產生了哪些影響？
日本神經生物標記市場按類型是如何分類的？
日本神經生物標記市場按應用領域是如何分類的？
日本神經生物標記市場依最終用途分類的情況如何？
日本神經生物標記市場價值鏈的不同階段有哪些？
日本神經生物標記市場的主要促進因素和挑戰是什麼？
日本神經生物標記市場的結構是怎麼樣的？主要企業有哪些？
日本神經生物標記市場競爭有多激烈？

Japan neurological biomarkers market size reached USD 623.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 986.8 Million by 2034, exhibiting a growth rate (CAGR) of 5.23% during 2026-2034. The inflating adoption of effective treatment plans and the escalating demand for faster drug development are primarily driving the market growth.

Access the full market insights report Request Sample

Neurological biomarkers , found in either the blood or cerebral spinal fluid (CSF), serve to facilitate the identification of brain disorders and track the advancement of diseases. These biomarkers primarily originate from genetic mutations, levels of metabolites, brain imaging, and alterations in the expression of proteins or modifications after translation. With their ability to identify biological reactions to experimental medications and assist in the exploration of novel targets for therapeutic intervention, neurological biomarkers play a significant role in clinical applications throughout the drug development process. Currently, scientists analyze the concentrations of these biomarkers to enable non-invasive testing, early diagnosis, and the customization of treatments.

JAPAN NEUROLOGICAL BIOMARKERS MARKET TRENDS:

The Japan neurological biomarkers market is witnessing a notable upsurge owing to the escalating prevalence of neurological disorders, including conditions like stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). This surge in neurological disorders has generated a pressing demand for accelerated drug development, thereby driving the market growth. Besides this, biomarkers play a pivotal role in measuring the effectiveness of novel medications and therapeutic approaches, contributing significantly to this momentum. Additionally, the growing acceptance of minimally invasive procedures and personalized medicine practices is serving as another crucial catalyst for market expansion in the region. Furthermore, as various neurological disorders often exhibit shared characteristics, there is an increasing requirement for multiple biomarkers to differentiate between specific diseases and their subtypes, further fueling market demand. Apart from this, advancements in mass spectrometry and imaging techniques have facilitated the rapid evaluation of numerous biochemical markers and structural changes within the brain, enabling enhanced diagnostic capabilities. This, coupled with the introduction of digital biomarkers and the continual rise in the number of clinical trials, is expected to further propel the growth of the Japan neurological biomarkers market in the forthcoming years.

JAPAN NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION:

Type Insights:

To get detailed segment analysis of this market Request Sample
Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others
Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others

Application Insights:

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others

End Use Insights:

Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan neurological biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan neurological biomarkers market?
What is the breakup of the Japan neurological biomarkers market on the basis of type?
What is the breakup of the Japan neurological biomarkers market on the basis of application?
What is the breakup of the Japan neurological biomarkers market on the basis of end use?
What are the various stages in the value chain of the Japan neurological biomarkers market?
What are the key driving factors and challenges in the Japan neurological biomarkers?
What is the structure of the Japan neurological biomarkers market and who are the key players?
What is the degree of competition in the Japan neurological biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Neurological Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Neurological Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Neurological Biomarkers Market - Breakup by Type

6.1 Genomic Biomarkers
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Proteomic Biomarkers
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Metabolomic Biomarkers
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Imaging Biomarkers
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2020-2025)
- 6.5.2 Market Forecast (2026-2034)

7 Japan Neurological Biomarkers Market - Breakup by Application

7.1 Alzheimer's Disease
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Parkinson's Disease
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Multiple Sclerosis
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Autism Spectrum Disorders
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2020-2025)
- 7.5.2 Market Forecast (2026-2034)

8 Japan Neurological Biomarkers Market - Breakup by End Use

8.1 Hospital Laboratories
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Clinical Diagnostic Centers
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Research Organizations
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Others
- 8.4.1 Historical and Current Market Trends (2020-2025)
- 8.4.2 Market Forecast (2026-2034)

9 Japan Neurological Biomarkers Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Type
- 9.1.4 Market Breakup by Application
- 9.1.5 Market Breakup by End Use
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Type
- 9.2.4 Market Breakup by Application
- 9.2.5 Market Breakup by End Use
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Type
- 9.3.4 Market Breakup by Application
- 9.3.5 Market Breakup by End Use
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Type
- 9.4.4 Market Breakup by Application
- 9.4.5 Market Breakup by End Use
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Type
- 9.5.4 Market Breakup by Application
- 9.5.5 Market Breakup by End Use
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Type
- 9.6.4 Market Breakup by Application
- 9.6.5 Market Breakup by End Use
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Type
- 9.7.4 Market Breakup by Application
- 9.7.5 Market Breakup by End Use
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Type
- 9.8.4 Market Breakup by Application
- 9.8.5 Market Breakup by End Use
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Neurological Biomarkers Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Services Offered
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Services Offered
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Services Offered
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Services Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Services Offered
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Neurological Biomarkers Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis